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 Introduction 
 Pattern recognition receptors (PRRs) are a vital part of 
innate host defense. In several diseases, however, PRR 
signaling can be harmful to the host. Tissue damage can 
be inflicted by excessive pathogen-induced PRR signal-
ing. Yet during the last decade several diseases were iden-
tified in which profuse PRR signaling was caused by en-
dogenous factors. The cryopyin-associated periodic syn-
drome (CAPS) is an example of genetically predisposed 
NLRP3 [nucleotide oligomerization domain (NOD), leu-
cin-rich repeat- and pyrin domain-containing 3 protein] 
overactivation, resulting in mild to debilitating systemic 
inflammation  [1, 2] . Multiple complex disorders have 
been linked to NLRP3 dysfunction, including gout, type 
2 diabetes mellitus and atherosclerosis  [1, 3, 4] . Although 
NLRP3 is the best-characterized inflammasome-related 
PRR, and it was shown to respond to an impressive array 
of endogenous and exogenous stimuli ranging from ATP 
to reactive oxygen species, the exact ligand sensing mech-
anism of NLRP3 remains unknown  [5] . NLRP3 is part
of an inflammasome. Inflammasomes are multiprotein 
complexes that upon ligand binding by certain PRRs 
 activate caspase-1, which in turn activates the potent pro-
 Key Words 
 Autoimmunity   Epithelium   Host defense   Immune 
response   Pathogen-associated molecular patterns   
Pattern recognition receptors   Toll-like receptor   Skin 
 Abstract 
 Pattern recognition receptors (PRRs) evolved to protect or-
ganisms against pathogens, but excessive signaling can in-
duce immune responses that are harmful to the host. Puta-
tive PRR dysfunction is associated with numerous immune 
disorders that affect the skin, such as systemic lupus erythe-
matosus, cryopyrin-associated periodic syndrome, and pri-
mary inflammatory skin diseases including psoriasis and 
atopic dermatitis. As yet, the evidence is often confined to 
genetic association studies without additional proof of a 
causal relationship. However, insight into the role of PRRs in 
the pathophysiology of some disorders has already resulted 
in new therapeutic approaches based on immunomodula-
tion of PRRs.  Copyright © 2012 S. Karger AG, Basel 
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inflammatory cytokines IL-1  , IL-18 and IL-33 ( fig. 1 ). 
Since IL-1  is an extremely potent inflammatory cyto-
kine, its activation is strictly regulated and requires more 
than inflammasome activation. The two-step model of 
IL-1  activation holds that prior to inflammasome acti-
vation the precursor of IL-1  (pro-IL-1  ) needs to be 
transcribed, for which priming with TLR ligands or cy-
tokine tumor necrosis factor-  (TNF-  ) is required 
( fig. 1 )  [5, 6] . This is one of the many cases in which PRR 
cooperation is imperative. The PRRs that associate with 
inflammasomes are the NLRs NLRP1, NLRP3, NLRC4 
[NOD-, leucin-rich repeat- and caspase-associated re-
cruitment domain (CARD)-containing 4  [7] , the DNA 
sensors AIM2 (absent in melanoma 2)  [8–10] and IFI16 
(interferon, gamma-inducible protein 16)  [11] , and RIG-I 
(retinoic-acid-inducible gene I)  [12] .
 Fig. 1. The inflammasomes. Inflammasomes are protein com-
plexes that activate caspase-1, which in turn activates the proin-
flammatory cytokine IL-1  . IL-1  production requires two sig-
nals. First, activation of multiple PRRs may lead to NF-  B activa-
tion, resulting in the production of pro-IL-1  , the precursor of 
IL-1  . Second, activation of an inflammasome results in activa-
tion of caspase-1, which in turn cleaves pro-IL-1  into the active 
cytokine. The PRRs that associate with inflammasomes are 
NLRP1, NLRP3, NLRC4, AIM2, IFI16 and RIG-I, each recogniz-
ing particular PAMPs and DAMPs. The adaptor protein ASC is 
required in all inflammasome complexes to bridge the interaction 
between upstream PRRs and inflammatory caspases through its 
amino-terminal pyrin domain (PYD) and carboxy-terminal 
CARD, respectively. The major ligands of the PRRs are depicted 
in bold. NLRP1 = Nucleotide-binding oligomerization domain 
(NOD)-like receptor (NLR) family PYD-containing protein 1. 
Adaptor and signaling proteins: IRAK = IL-1R-associated kinase; 
SYK = spleen tyrosine kinase; ASC = apoptosis-associated speck-
like protein containing a CARD; ssRNA = single-stranded RNA; 
MDP = muramyl dipeptide; UVB = ultraviolet B radiation. 
 PRRs in Immune Disorders Affecting the 
Skin 
J Innate Immun 2012;4:225–240 227
 The levels of evidence for associations between dis-
eases and PRRs differ greatly. In some, there is a clear 
causal relationship between a mutation in a PRR gene and 
excessive inflammation, whereas in other diseases, only 
differences in expression levels of certain PRRs or asso-
ciations with single nucleotide polymorphisms (SNPs) in 
genome-wide association studies were reported. This re-
view summarizes the detrimental roles PRRs can play in 
primary inflammatory skin diseases and systemic dis-
eases with skin manifestations.
 PRRs as Villains in Primary Skin Disorders 
 Despite the fact that these disorders principally affect 
the skin, several of them can also give systemic symp-
toms, and can display abnormalities in circulating im-
mune cells or inflammatory mediators. The inflamma-
tory skin disorders that are associated with PRRs are list-
ed in  table 1 .
 Primary Skin Disorders in Which a Role of PRRs Is 
Suspected 
 Psoriasis 
 Psoriasis is a chronic inflammatory skin disease char-
acterized by erythematosquamous plaques. It is associ-
ated with skin barrier abnormalities and T helper cell 1 
(Th1) and Th17 immune responses  [13, 14] . More recent-
ly, the innate immune system was found to play a role
too. The expression of multiple antimicrobial proteins 
(AMPs), including human   -defensin-2 (hBD-2), is 
strongly increased in psoriatic plaques  [13] , which could 
well be a downstream effect of PRR signaling. Several 
groups investigated PRR expression in psoriatic lesions. 
Lesional TLR2 mRNA and protein expression levels are 
similar to those in normal skin  [15, 16] , although two old-
er studies suggested differently  [17, 18] . Transforming 
growth factor alpha, which is induced in psoriasis, was 
shown to increase TLR5 and TLR9 expression and func-
tion in keratinocytes. TLR2, TLR5 and TLR9 ligands in-
duce the expression of human   -defensins in primary ke-
ratinocytes  [15, 19] . Also, TLR2, TLR3 and TLR4 ligands 
were shown to induce the psoriasis-associated cytokine 
TNF-  in human keratinocytes  [18] . It is, however, con-
troversial whether TLR4 is expressed in primary human 
keratinocytes, because several authors did not find TLR4 
expression or effects of lipopolysaccharide (LPS) stimula-
tion in these cells  [15, 20] .
 Interestingly, topical application of imiquimod, a li-
gand for both TLR7 and TLR8, has been described as
aggravating psoriatic lesions, but also inducing de novo 
psoriasis  [21–24] . TLR7 and TLR8 signaling leads to a 
type I interferon (IFN) response. IFN-  -producing plas-
macytoid dendritic cells (pDCs) are thought to be impor-
tant in the induction of psoriasis  [25] . Moreover, psoriasis 
was reported to be induced or exacerbated by treatment 
with IFN-  or IFN-  for various indications (hepatitis C 
 [26] , chronic myeloid leukemia  [27] or multiple myeloma 
 [28] ). In a mouse model, daily application of imiquimod 
induced psoriasis-like lesions with increased epidermal 
expression of IL-23, IL-17A and IL-17F, and an increase 
in splenic Th17 cells. However, this phenotype was pre-
vented in mice deficient in the IL-23 or IL-17 receptor. 
This study provided a link between TLR7 or TLR8 signal-
ing and the IL-23/IL-17 axis, which is important in the 
pathogenesis of psoriasis  [29] . The role of other type I 
IFN-inducing PRRs is unclear, since in one study RIG-I 
and MDA5 (melanoma differentiation-associated gene 5) 
were slightly upregulated  [30] , while others did not find 
any difference in RLR (RIG-like helicase receptor family) 
expression levels  [15] .
 A meta-analysis demonstrated a lack of association be-
tween  NOD2 polymorphisms and psoriasis and psoriatic 
arthritis, suggesting that this NLR is not a susceptibility 
gene for psoriasis  [31] .
 Compared to normal skin, the CLR dectin-1 is in-
creased in the epidermis in psoriatic plaques at both the 
mRNA and protein level. MRC1 (macrophage mannose 
receptor 1) mRNA expression was also upregulated  [15] . 
In monocytes and macrophages, dectin-1 signaling in-
duces IL-23, which in turn promotes differentiation of 
Th17 cells  [32] . As a sensor of fungal   -glucan, dectin-1 
signaling stimulates immune cells to produce antifungal 
AMPs, which are highly expressed in psoriasis lesions. 
Stimulation of primary human keratinocytes with   -
glucan or heat-killed  Candida , however, did not induce 
proinflammatory cytokines or AMPs, either with or 
without TLR2, TLR5 or MRC1 costimulation  [15] . Pos-
sibly, dectin-1 expression levels were too low for proper 
functioning, or costimulation with other ligands is re-
quired.
 LL37, one of the upregulated AMPs in psoriasis, forms 
aggregates with extracellular self-DNA that can enter 
pDCs, activate TLR9 and trigger type I IFN production 
 [33] . Recently, LL37 was reported to neutralize cytosolic 
DNA in keratinocytes and block activation of the AIM2 
inflammasome. The authors found upregulation of AIM2 
in psoriatic lesional skin and a 3-fold induction of IL-1  
secretion by keratinocytes upon stimulation with double-
stranded DNA (dsDNA)  [34] .
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Disease Genetic association Endogenous expression in 
affected human tissues
PRR-mediated effect on immune
response to ligands in human cells
Functional association
in mice
Primary skin disorders
Primary skin disorders in which a role of PRRs is suspected
Psoriasis AIM2: increased
Dectin-1: increased
MRC1: increased
In keratinocytes:
TLR2: induction of hBD-2 and TNF-
TLR3: induction of TNF-
TLR4: induction of TNF- or no effect
TLR5: induction of hBD-2
TLR9: induction of hBD-2
Dectin-1: no effect of -glucan +/– 
TLR2 or TLR5 or MRC1 ligands
AIM2: IL-1 activation
In monocytes:
Dectin-1: induction of IL-23
TLR7/TLR8: imiquimod
induced psoriasis-like disease
AD TLR2 A-16934T promotor SNP: 
disease severity
TLR2 R753Q SNP: disease severity 
and increased colonization with
S. aureus
TLR9 C-1237T promotor SNP: 
association in subgroup 
NOD1 SNPs: association in some
Dectin-1: increased
MRC1: increased
TLR1: increased
TLR2: normal or 
decreased
In keratinocytes:
TLR2/TLR6: induction of TSLP
ACD MyD88 RNAi: inhibited
nickel-induced inflammation
IRAK1 RNAi: reduced
nickel-induced inflammation
TLR4 RNAi: inhibited
nickel-induced inflammation
Caspase-1: mediated IL-1 activation
upon TNCB and SDS
Tlr2–/–/Tlr4–/–: 
impaired TNCB-induced 
ACD
Tlr4–/–: no effect on
TNCB-induced ACD
hTLR4, not mTlr4: 
mediated nickel-induced 
ACD
Asc–/–: reduced 
TNCB-induced ACD
Nlrp3–/–: reduced 
TNCB-induced ACD
Nlrp12–/–: reduced 
oxazolone or FITC ACD
Primary skin disorders in which a role of PRRs is speculative
Rosacea TLR2: increased TLR2: induction of kallikrein 5
Vitiligo NLRP1 SNPs: association with 
generalized vitiligo
Stevens-
Johnson
syndrome
TLR3 SNPs: association
Systemic immune disorders affecting the skin
Monogenic disorders directly linked to a mutation in a PRR gene
CAPS NLRP3 mutations: autosomal 
dominant, disease-causing
NLRP3 mutants: excessive 
endogenous and PAMP-induced 
IL-1 activation
NLRP12AD NLRP12 mutations: autosomal 
dominant (?), disease-causing
NLRP12 mutants: impaired inhibition 
of NF-B signaling in some; 
increased IL-1 and ROS activation in 
others
Blau
syndrome
NOD2 mutations:
disease-causing
NOD2 mutants: constitutive 
activation of NF-B 
Table 1. P RRs implicated in immune disorders affecting the skin
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 Atopic Dermatitis 
 Atopic dermatitis (AD) is a common chronic inflam-
matory skin disease that mainly affects children and is 
characterized by pruritus, eczematous lesions and xero-
sis. AD is associated with skin barrier abnormalities and 
a Th2 immune response  [13] . AD lesions display lower 
levels of AMPs than psoriatic plaques  [35, 36] , and are 
often infected with  Staphylococcus aureus , which is asso-
ciated with AD flares and severity  [37, 38] . Herpes sim-
plex virus (HSV) infections can also exacerbate AD and 
 Candida species often colonizes atopic skin  [37] . Defects 
in the innate immune system were hypothesized to pre-
dispose to AD development and to colonization with 
these pathogens. Hence, differences in PRR expression 
Disease Genetic association Endogenous expression in 
affected human tissues
PRR-mediated effect on immune
response to ligands in human cells
Functional association
in mice
Disorders caused by overstimulation of PRR by endogenous ligands
Gout NLRP3: excessive uric-acid-induced 
IL-1 activation, provided LPS is 
present
Nlrp3–/–: no gout upon 
urate injection
Asc–/–: no gout upon urate 
injection
Pseudogout NLRP3: excessive calcium 
pyrophosphate dihydrate-induced 
IL-1 activation, provided LPS is 
present
Systemic immune disorders in which a role of PRRs is suspected
BD TLR4 SNP: more prevalent in
HLA–B51+ patients
TIRAP SNP:  associated in one 
population
SLE TLR5 SNP: protective
TIRAP SNP: decreased
susceptibility
HSP70 SNPs: association in some, 
but controversial
TLR2, TLR7, TLR9, 
AIM2 and IFI16: mRNA 
increased in PBMCs
TLR2, TLR4 and/or TLR9: in serum
increased HMGB1 (ligand) protein 
and anti-HMGB1 antibodies
TLR7: overexpression induced 
autoimmunity
Tlr2–/–: impaired autoanti-
body
production induced by 
nucleosomes containing 
HMGB1
Tlr7 overexpression: 
induced autoimmunity
TLR9–/–: decreased or 
increased disease in SLE 
mouse model
GVHD NOD2 SNPs: increased 
susceptibility
Recipient Tlr9–/–: 
reduced GVHD
Donor Tlr9–/–: no effect
Tlr9 blocking by iODN: 
reduced GVHD 
Recipient Myd88: no effect 
Recipient TRIF: no effect 
Recipient TLR2–/–: no effect
Recipient TLR4–/–: no effect 
or more severe GVHD
Donor TLR4–/–: no effect or 
reduced GVHD
Recipient NOD2–/–:
more severe GVHD 
Donor NOD2–/–: no effect
Systemic immune disorders in which a role of PRRs is speculative
Sarcoidosis NOD2 SNPs: association with 
severe pulmonary disease, not in 
general
Schnitzler
syndrome
NLRP3 V198M SNP in a single 
patient, to date not in others
Inflammasome: increased IL-1 
activation upon stimulation with LPS
Table 1 (continued)
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and function became research targets.  S. aureus -diacyl-
ated lipoproteins were shown to induce expression of thy-
mic stromal lymphopoietin (TSLP), which is highly ex-
pressed by keratinocytes in skin lesions of patients with 
AD. This process required signaling of the TLR2/TLR6 
heterodimer and was enhanced by Th2 cytokines  [39] . 
The role of TLR2 in AD is controversial, as is the case in 
other diseases. One study reported the association of the 
TLR2 A-16934T promoter polymorphism with severe 
AD, which did not affect TLR2 mRNA expression and 
resulted in decreased TLR2-induced IL-6, but not TNF-  
production  [40] . In one population the TLR2 R753Q 
polymorphism was associated with AD disease severity 
and increased colonization with  S. aureus  [41] . Previous-
ly, this polymorphism had been implicated in  S. aureus 
infections  [42] . The TLR2 R753Q polymorphism led to 
decreased cell surface expression of TLR2 in CD3/CD28-
activated CD4+ T cells, and impaired TLR2-mediated 
IL-8 secretion by monocytes  [43] . In other populations, 
no associations between TLR1, TLR2, TLR4 and TLR6 
polymorphisms and AD were found  [44, 45] . The data on 
TLR2 protein expression levels in AD lesions are also 
conflicting, since one study reported no difference with 
normal skin  [16] , whereas another study reported de-
creased TLR2 and increased TLR1 expression in AD le-
sions  [46] . In this study, TLR4 and TLR9 protein expres-
sion levels were similar in AD lesions and normal skin 
 [46] . The C-1237T polymorphism in the TLR9 promoter 
was significantly associated with AD in a subgroup of 
patients, and resulted in significantly higher promoter 
activity. This association was not seen in a case-control 
cohort in the same study, so it may only apply to some 
cases of AD  [47] . One genetic study revealed an associa-
tion of  NOD1 polymorphisms with AD  [48] , but in other 
studies, genetic associations of AD with  NOD1 ,  NOD2 or 
 NLRP12 were only slightly significant, which renders the 
pathophysiological implications questionable  [49, 50] .
 A comprehensive study on epidermal PRR mRNA ex-
pression showed that expression of the majority of PRRs 
was similar in psoriasis, AD and normal skin. In AD, 
dectin-1 was upregulated 6-fold and MRC1 10-fold  [15] . 
Progenitor-derived mast cells from AD patients were 
shown to display lower dectin-1 expression, but the im-
plications are yet to be determined  [51] .
 Allergic Contact Dermatitis 
 Allergic contact dermatitis (ACD) is a type IV-delayed 
hypersensitivity reaction in the skin typically after sen-
sitization by haptens. In mice, the concomitant absence 
of Tlr2 and Tlr4 prevented the induction of ACD to 
2,4,6-trinitro-1-chlorobenzene (TNCB). Also, in Tlr4/IL-
12R  2 double knockout mice, dendritic cell (DC)-medi-
ated sensitization, generation of effector T cells, and the 
subsequent contact hypersensitivity response to TNCB, 
oxazolone, and fluorescein isothiocyanate were absent. 
This was not the case in TLR4 or IL-12 single knockout 
mice  [52] . Epicutaneous immunization with protein an-
tigen is applied as desensitization because it induces sup-
pression of subsequent T cell-dependent contact hyper-
sensitivity reactions after active immunization. Ptak et 
al.  [53] found that this suppression can be reversed by 
crude bacterial components and purified TLR2, TLR3, 
TLR4, and TLR9 ligands. Also, the effect of TLR4 ligand 
LPS was not observed in Tlr4 mutant C3H/HeJ mice, 
which indicates that this effect was dependent upon in-
tact TLR4 signaling. The inflammatory response in nick-
el ACD was shown to be TLR4 dependent. Interestingly, 
mouse Tlr4 could not generate this response, but trans-
genic expression of human TLR4 in TLR4-deficient mice 
allowed efficient sensitization to nickel and elicitation of 
ACD  [54] .
 Watanabe et al.  [55] showed involvement of the in-
flammasome in ACD. In primary human keratinocytes, 
TNCB and SDS induced IL-1  activation in a caspase-1-
dependent manner. In Asc and Nlrp3 knockout mice, 
TNCB-induced ACD was reduced.
 NLRP12 is one of the latest identified NLRs. In two 
models of ACD (oxazolone and FITC),  Nlrp12 -deficient 
mice exhibited attenuated inflammatory responses. 
 Nlrp12 knockout DCs were less capable of migrating to 
draining lymph nodes, and both  Nlrp12 knockout DCs 
and neutrophils failed to respond to chemokines in vitro 
 [56] .
 Primary Skin Disorders with Speculative Associations 
with PRRs 
 In other skin disorders, the evidence for a role of PRRs 
is still more speculative, although it may have important 
implications. We will mention three examples of these.
 Rosacea 
 Rosacea is a common skin disease that is characterized 
by facial inflammation, abnormal vascular dilatation and 
proliferation, and formation of granulomas. Symptoms 
are exacerbated by external triggers, such as UV light, 
heat, and a variety of microbes. TLR2 stimulation in-
duced expression of kallikrein 5, a critical protease in-
volved in the pathogenesis of rosacea, since it processes 
cathelicidin  [16] . The increased TLR2 expression in rosa-
cea may cause increased susceptibility to pathogen- and 
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damage-associated molecular patterns (PAMPs and 
DAMPs) that trigger disease  [16] .
 Vitiligo 
 Vitiligo is an autoimmune disease characterized by 
the destruction of melanocytes in the epidermis, result-
ing in depigmented maculae. It is associated with several 
other autoimmune disorders including autoimmune thy-
roid disease, rheumatoid arthritis, systemic lupus erythe-
matosus (SLE), and diabetes  [57] .  NLRP1 genetic variants 
have been associated with vitiligo  [57–59] , which is inter-
esting from a pathophysiological point of view, since 
NLRP1 is part of an inflammasome that activates IL-1  
and can result in apoptosis. The functional aspects re-
quire further investigation.
 Stevens-Johnson Syndrome 
 Stevens-Johnson syndrome and the related toxic epi-
dermal necrolysis are severe acute-onset mucocutaneous 
disorders that can be induced by drugs or pathogens. In 
Japanese patients,  TLR3 polymorphisms were associated 
with Stevens-Johnson syndrome and toxic epidermal 
necrolysis  [60] , while in another population  TLR9 poly-
morphisms were not  [61] .
 PRRs in Systemic Inflammatory Disorders with Skin 
Manifestations 
 PRRs are implicated in many systemic disorders, such 
as the autoinflammatory syndromes, which are charac-
terized by a predisposition towards excessive innate im-
mune activation, often affecting the skin  [62] . Several au-
toinflammatory diseases somehow affect PRR signaling 
pathways, but in this review we chose to discuss those 
that are directly linked to PRRs. We will also discuss ex-
amples of multifactorial diseases in which PRRs were im-
plicated, as listed in  table 1 .
 Monogenic Disorders Directly Linked to a Mutation in 
a PRR Gene 
 Cryopyrin-Associated Periodic Syndrome 
 CAPS refers to a spectrum of autoinflammatory 
diseases, previously known as familial cold associated
periodic syndrome, Muckle-Wells syndrome, and the de-
bilitating chronic infantile neurologic, cutaneous, articu-
lar syndrome. The latter was also known as neonatal-
onset multisystem inflammatory disease   [1, 2] . CAPS
is clinically characterized by urticarial-like skin rashes 
which may be cold-induced, recurrent fevers, arthralgia 
or arthritis, ocular symptoms, sometimes amyloidosis, 
and, in severely affected patients, severe neurological 
symptoms  [63] . These diseases were collectively classified 
as CAPS upon recognition that all three were caused by 
heterozygous mutations in NLRP3, previously referred to 
as NALP3 or cryopyrin  [64, 65] . These are regarded as 
gain of function mutations, resulting in a hyperactive or 
constitutively active inflammasome, leading to systemic 
IL-1  -induced inflammation. Monocytes and macro-
phages from Muckle-Wells syndrome patients display a 
basal secretion of mature IL-1  in the absence of any ex-
ternal stimulus  [66] . Together, these data formed the ra-
tionale for trials with IL-1 blocking therapies. Indeed, the 
IL-1 receptor antagonist anakinra, the IL-1 receptor-Fc 
fusion protein rilonacept, and the human IgG1 anti–IL-
1  monoclonal antibody canakinumab are all successful 
in preventing inflammation in CAPS  [2, 67–69] .
 NLRP12-Associated Periodic Syndrome 
 A very rare hereditary periodic fever syndrome results 
from mutations in the  NLRP12  gene, and manifests with 
mainly cold-induced recurrent fevers, arthralgia, and in 
some cases urticarial rashes or abdominal pain  [70–72] . 
The pathophysiology is not completely clear yet. NLRP12 
was previously shown to inhibit nuclear factor-  B (NF-
  B) signaling  [73] , and in some of the  NLRP12 mutations 
a clear reduction of these inhibitory properties could be 
found, in keeping with a loss of function  [70] , but this was 
not true in all cases  [74] . In another family, monocytes 
produced more IL-1  and reactive oxygen species upon 
stimulation with PAMPs  [71] . Altogether,  NLRP12 muta-
tions cause an autoinflammatory syndrome through in-
creased NF-  B and/or IL-1  signaling.
 Blau Syndrome 
 Blau syndrome, also known as early-onset sarcoidosis, 
is a rare autosomal dominant disorder which is charac-
terized by granulomatous arthritis, uveitis and skin rash 
 [75] . Various mutations in the  NOD2 gene were found in 
patients with Blau syndrome, and all mutations were as-
sociated with constitutive activation of the transcription 
factor NF-  B  [75] . These mutations confer a gain of func-
tion to NOD2, while Crohn’s disease-associated  NOD2 
 variants impair NF-  B activation  [76, 77] .
 Systemic Immune Disorders in Which a Role of PRRs 
Is Suspected  
 Gout and Pseudogout 
 Monosodium urate and calcium pyrophosphate dihy-
drate crystals were long known to cause arthritis in gout 
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and pseudogout, respectively. In the so-called tophi, uric 
acid depositions induce inflammation in the skin. Both 
monosodium urate and calcium pyrophosphate dihy-
drate crystals were shown to be able to activate the NLRP3 
inflammasome in vitro , provided there was costimula-
tion with LPS, resulting in excessive IL-1  production 
 [78] . The authors showed that macrophages from mice 
deficient in various components of the inflammasome, 
such as pro-caspase-1, ASC or NLRP3, did not respond to 
injection of urate crystals. The excessive production of 
IL-1  provides a rationale for IL-1  blocking therapies. 
Indeed, anakinra and rilonacept proved highly effective 
in clinical trials in gout patients  [79, 80] .
 Behçet’s Disease 
 Behçet’s disease (BD) is a multisystem disease charac-
terized by recurrent oral and genital ulcers, relapsing uve-
itis, and articular, neurologic, vascular, intestinal and 
pulmonary manifestations. Several groups studied  NOD2 
polymorphisms in BD patients, but found no association 
 [81–83] . SNP analyses of  TLR2, TLR4, CD14 and  TLR9 in 
BD patients was also negative  [84–88] . However, the 
S180L polymorphism in  Toll/interleukin receptor 1 do-
main-containing adaptor protein (TIRAP) , a protein in-
volved in TLR2 and TLR4 signaling, was significantly as-
sociated with BD in UK, but not Middle Eastern, patients 
 [86] . Also, a  TLR4 variant was significantly more preva-
lent in HLA-B51-positive, but not HLA-B51-negative BD 
patients, compared with healthy control participants, 
which suggests a synergistic increase in susceptibility of 
BD in this population  [89] . Thus, most genetic studies on 
PRRs in BD showed no association.
 Systemic Lupus Erythematosus 
 SLE is predominantly regarded as a disorder of the 
adaptive immune system, but recent studies point to-
wards a concomitant role of innate immune responses 
 [90] . In murine SLE models, autoantibodies bind DNA or 
chromatin released from dying cells, forming complexes 
that can stimulate IFN-  production by DCs via TLR9 
 [91–94] . In addition, TLR9/MyD88 (myeloid differentia-
tion factor 88) signaling is required for class switching to 
pathogenic IgG2a and 2b autoantibodies in autoreactive 
B cells in SLE, resulting in a pathogenic loop  [95] . The role 
of TLR9 is controversial, however, since others found that 
 TLR9 knockdown resulted in exacerbation of autoim-
munity rather than reduction  [96] . Moreover, TLR9 was 
found to regulate TLR7- and MyD88-dependent autoan-
tibody production and disease in a murine SLE model 
 [97] . Possibly, differences between mouse strains account 
for these discrepancies.  TLR9 polymorphisms were asso-
ciated with lupus nephritis in a Chinese Han population, 
but the functional consequences of the polymorphisms 
are unclear  [98] . Patients with active SLE displayed an
increased number of TLR9-positive B cells, which cor-
related with elevated titers of autoantibodies against
dsDNA. In vitro , serum from patients with SLE upregu-
lated expression of TLR9 on plasma cells  [99] . Tian et al. 
 [100] showed that B cells and pDCs can be activated by 
immune complexes that contain DNA and high mobility 
group box (HMGB)-1 in a TLR9- and MyD88-dependent 
manner involving  RAGE  (receptor for advanced glyca-
tion end products). HMGB1 is also recognized by TLR2 
and TLR4  [101] . In the sera of SLE patients, HMGB1 and 
anti-HMGB1 antibodies are often found  [102] , as are 
HMGB1-containing nucleosomes  [103] . These HMGB1-
containing nucleosomes stimulated the production of 
proinflammatory cytokines in macrophages, and in-
duced autoantibody production in BALB/c mice, both in 
a TLR2-dependent manner  [103] .
 Activation of TLR7 and TLR8 by RNA and RNA con-
taining immune complexes is also implicated in the 
pathogenesis of SLE  [91, 92, 104, 105] .  TLR7 and  TLR8 
are encoded on the X chromosome, which is intriguing 
since 90% of SLE cases occur in women. Hypothetically, 
a copy number increase of the  TLR7 or  TLR8 genes could 
account for this predominance. Indeed, overexpression 
of  TLR7 triggered autoimmune responses in mice and 
transgenic cell lines  [106] . In PBMCs (the peripheral 
blood mononuclear cells) of patients with SLE, mRNA 
expression levels of TLR2, TLR7 and TLR9 were elevat-
ed, whereas TLR3, TLR4, TLR5 and TLR8 remained the 
same  [107] . A  TLR5  stop codon polymorphism abrogat-
ing TLR5 function was found to be associated with resis-
tance to SLE  [108] . Polymorphisms of some, but not all 
investigated heat shock protein 70 (HSP70) genes were 
associated with SLE  [109, 110] . Some studies suggest 
HSP70 is an endogenous TLR2 and TLR4 ligand  [111, 
112] . These associations are controversial, however, since 
some argue that contaminating PAMPs are responsible 
for the reported in vitro cytokine effects of HSPs, as 
highly purified HSPs do not show any cytokine effects 
 [113] .
 TLR3, which recognizes dsRNA, is absent in B cells, 
but its activation on glomerular mesangial cells and an-
tigen-presenting cells was shown to aggravate lupus ne-
phritis in a mouse model  [114] . However, TLR3 costim-
ulation did not influence TLR7-induced complex glo-
merulonephritis in this mouse model  [104] . The S180L 
polymorphism in the TLR2 and TLR4 pathway adaptor 
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protein  TIRAP was shown to decrease susceptibility to 
SLE in a Colombian population  [115] .
 The majority of studies investigated the role of TLRs 
in SLE, but other PRRs may well be involved too. Kim-
kong et al.  [116] found increased mRNA expression levels 
of IFI16 and AIM2 in PBMCs of SLE patients. Since these 
are cytosolic dsDNA receptors, they may well be involved 
in the immune reactions against host-derived DNA.
 Graft-versus-Host Disease 
 Graft-versus-host disease (GVHD) occurs when do-
nor cells from a bone marrow transplant attack healthy 
tissues of the host. The adaptive immune system is 
thought to be the main culprit, but recent findings impli-
cate the host innate immune system as well. In the case 
of intestinal GVHD, microbiota may modulate innate 
immune response via PRRs  [117] . For example, in murine 
experimental GVHD models,  Tlr9 deficiency in the host 
but not the donor reduced intestinal immunopathology 
and GVHD-related mortality. GVHD was also reduced 
in mice upon treatment with synthetic inhibitory oligo-
deoxynucleotide (iODN) that blocks TLR9 signaling. 
However, it is not clear whether TLR9 inhibition impairs 
the graft-versus-tumor response too, which would be 
highly undesirable  [116] . No increased GVHD was seen 
in recipient mice deficient in the crucial TLR adaptor pro-
teins  Myd88  (myeloid differentiation factor 88) or  Trif 
 (Toll-interleukin 1 receptor-domain-containing adapter-
inducing IFN-  ) . Recipient  Tlr2 deficiency did not affect 
GVHD outcome in mice. Recipient  Tlr4 deficiency did 
not affect GVHD in two murine studies, and more severe 
GVHD was seen in another. Donor  Tlr4 deficiency did 
not affect GVHD in one murine study, but decreased 
GVHD severity in two others, while graft-versus-leuke-
mia activity was preserved in one  [117] .  NOD2 polymor-
phisms were associated with GVHD in human transplant 
recipients  [118, 119] . In mice models,  Nod2- deficient 
transplant recipients developed more severe GVHD, 
which was suggested to be caused by an increased activa-
tion status of DCs. NOD2 may therefore inhibit DC acti-
vation.  Nod2 knockout in donor mice did not affect 
GVHD  [120] .
 Systemic Immune Disorders in Which a Role of PRRs 
Is Speculative 
 Sarcoidosis 
 Sarcoidosis is characterized by granulomas affecting 
multiple organs. In one study, severe pulmonary sarcoid-
osis was associated with  NOD2 polymorphisms  [121] , but 
no  NOD2 association was found in sarcoidosis in gen-
eral  [122] . In a Japanese population, an association be-
tween  NOD1 gene polymorphisms and sarcoidosis sus-
ceptibility was found. The polymorphism was associated 
with reduced NOD1 expression and impaired NF-  B ac-
tivation upon infection with  Propionibacterium acnes 
 [123] .
 Schnitzler Syndrome 
 Schnitzler syndrome is an acquired syndrome charac-
terized by chronic urticaria paraproteinemia with signs 
and symptoms of systemic inflammation, such as ar-
thralgia and recurrent fever  [124] . It has similarities to the 
hereditary syndrome CAPS (see above), and IL-1  has 
been shown to be a central mediator of this disorder as 
well  [125, 126] . The exact pathophysiology is unknown. 
In 1 patient, the common variant V198M was found in 
the  NLRP3 gene  [127] , but not in others  [128] . The success 
of IL-1 inhibition as treatment in Schnitzler syndrome 
supports the suspicion of a role of PRRs in the pathophys-
iology of this rare syndrome  [126, 128, 129] .
 PRRs as Therapeutic Target in Immune Disorders 
 In view of their potential detrimental role in a multi-
tude of immune disorders, inhibition of PRR pathways 
may be a promising therapeutic approach. Conversely, 
PRR triggering has become a prominent topic in research 
on the immunomodulation of tumors, which we will dis-
cuss separately below.
 Immunomodulation of PRRs by Established 
Treatments in Immune Disorders 
 Calcineurin Inhibitors 
 Calcineurin inhibitors, such as cyclosporin A, tacroli-
mus and pimecrolimus, are used in the treatment of pso-
riasis and AD, and to prevent rejection in transplant pa-
tients. These agents suppress T cell-mediated immune 
responses, especially the production of proinflammatory 
cytokines in T cells, but recently evidence emerged that 
these calcineurin inhibitors also directly affect PRRs. In 
an immunohistochemical analysis of AD lesions, tacroli-
mus was found to reverse the increased TLR1 and de-
creased TLR2 expression levels  [46] . In normal human 
epidermal keratinocytes, pimecrolimus enhanced TLR2/
TLR6-induced expression of antimicrobial peptides. In-
terestingly, pimecrolimus also increased the functional 
capacity of keratinocytes to inhibit growth of  S. aureus , 
which often colonizes the skin of AD patients and causes 
superinfections of AD lesions  [130] .
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 Chloroquine 
 The antimalarial drugs chloroquine and hydroxychlo-
roquine have been applied as therapeutic agents for SLE 
for many years, although the mechanism of action is un-
clear. A direct role of modulation of PRRs is suggested by 
studies which show that they inhibit stimulation of TLR3, 
TLR8 and TLR9, presumably by direct binding to nucleic 
acids, thereby masking the TLR-binding epitopes  [131, 
132] .
 Immunomodulation of PRRs in Experimental Models 
of Immune Disorders 
 TLR9 Agonists 
 Not only inhibition, but also stimulation of PRRs 
might be of benefit in a therapeutic setting. Applications 
of TLR9 agonists, also referred to as CpG oligodeoxy-
nucleotides (ODN), are investigated in mouse models of 
allergy, since the Th1-biased immune response upon 
TLR9 activation may improve desensitization strategies 
in allergy treatment. Indeed, CpG ODN inhibited the 
Th2 response in allergic mice, preventing inflammatory 
disease manifestations. In human clinical trials with a 
conjugate of CpG ODN and part of the ragweed allergen 
as an allergy vaccine, selective redirection of the allergic 
Th2 response towards a Th1 response, and reduced al-
lergic symptoms were observed  [131] . Even though these 
studies were mainly on murine asthma models, they 
could have implications for the treatment of allergic cu-
taneous diseases.
 Of note, CpG ODN were also found to accelerate 
wound healing in mice and rhesus macaques, which 
could have therapeutic implications for chronic wounds 
in humans  [133, 134] .
 Combined TLR7/TLR9 Inhibition 
 TLR7 signaling is involved in the pathophysiology of 
SLE, while results on the role of TLR9 are conflicting. A 
specific inhibitor of TLR7 and TLR9, immunoregulatory 
sequence (IRS) 954, was shown to inhibit the induction 
of IFN-  by human pDCs upon stimulation with DNA 
and RNA viruses and isolated immune complexes from 
SLE patients  [91] . In SLE-prone mice, IRS 954 prevented 
progression of disease  [135] . Recently, TLR7 and TLR9 
signaling was shown to hamper glucocorticoid efficacy in 
SLE. Triggering of TLR7 and TLR9 by nucleic acid-con-
taining immune complexes or by synthetic ligands en-
hanced survival of IFN-  -producing pDCs  [136] . The 
role of TLR9 is controversial, however, since others found 
that TLR9 knockdown resulted in exacerbation of auto-
immunity rather than reduction  [96] .
 PRRs as Therapeutic Target in Tumors 
 Antitumor Immunomodulation of PRRs by 
Established Treatments 
 Imidazoquinolines 
 The prototype of a PRR-targeting therapy is imiqui-
mod, an imidazoquinoline compound which is a synthet-
ic agonist of TLR7 and to a lesser extent TLR8  [137, 138] . 
In contrast, imidazoquinolines were found to inhibit 
TLR3 and TLR9 signaling  [132] . Imiquimod has potent 
antitumor and antiviral properties and is an approved 
topical therapy for superficial basal cell carcinoma, ac-
tinic keratosis and genital warts  [139, 140] . There are mul-
tiple off-label indications for imiquimod, including HSV 
infections, verruca vulgaris, molluscum contagiosum, 
keloids, squamous cell carcinoma, Bowen’s disease, len-
tigo maligna, cutaneous T cell lymphoma, Kaposi’s sar-
coma, and Paget’s disease  [141, 142] . Imiquimod induces 
the production of several proinflammatory cytokines, 
stimulates T cell responses, and instigates the migration 
of Langerhans cells and pDCs to the lymph nodes  [138, 
143–145] . Moreover, at higher concentrations imiquimod 
induced apoptosis in basal cell carcinomas and melano-
ma metastases, but it is not clear whether this is a direct 
or indirect effect on the tumor cells  [138] . Resiquimod is 
a more potent TLR7- and TLR8-activating imidazoquin-
oline which was reported to be effective in the treatment 
of actinic keratosis  [146] and genital HSV-2 infections 
 [147, 148] . Because of its immunomodulating properties, 
imiquimod has been tested as an adjuvant in antitumor 
vaccines. In a murine model, topical imiquimod signifi-
cantly enhanced the protective antitumor effects of a live, 
recombinant  Listeria vaccine against melanoma  [149] . In 
melanoma patients, the combination of a NY-ESO-1 vac-
cine with topical imiquimod elicited both humoral and 
cellular responses in a significant fraction of patients, but 
the additive effect of imiquimod was unclear since a vac-
cine-only control arm was lacking  [150] . The downside of 
immunomodulation by TLR7 agonists is excessive im-
mune responses. Indeed, imiquimod often induces local 
skin inflammation at the application site, but it was also 
reported to aggravate psoriatic lesions and even to induce 
de novo psoriasis  [21–24] .
 Investigational Antitumor Immunomodulation of 
PRRs 
 Loxoribine 
 Loxoribine, another TLR7 agonist, enhances the pro-
duction of IFN, activates NK cells and B cells  [151] , and 
was recently found to induce maturation of human 
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monocyte-derived DCs and to stimulate their Th1- and 
Th17-polarizing capability  [152] . Hence, loxoribine has 
been under investigation for antiviral and antitumor 
properties  [153] , although not as intensively as imiqui-
mod.
 TLR9 Agonists 
 CpG ODN directly induce the activation and matura-
tion of pDCs and enhance differentiation of B cells into 
antibody-secreting plasma cells  [131] . As an adjuvant, 
CpG ODN were shown to induce strong CD4+ and 
CD8+ T cell responses and rapid production of antigen-
specific antibodies to many types of antigen  [154] . They 
are therefore considered as promising adjuvants in anti-
cancer vaccines, e.g. in the treatment of melanoma  [131, 
155–157] . In mice with cutaneous melanoma, combina-
tion therapy of topical CpG ODN with systemic dacar-
bazine inhibited tumor growth significantly more than 
with monotherapy with either agent  [156] . Importantly, 
TLR9 expression patterns differ between mice and hu-
mans, and CpG DNA are less stimulating in humans 
than in mice; therefore these results cannot automati-
cally be extrapolated to humans  [154] . In patient trials, 
monotherapy with the TLR9 agonist PF-3512676 in-
duced immune responses, but for optimal clinical effi-
cacy CpG ODN are currently under investigation as an-
timelanoma vaccine adjuvants  [155] .
 Conclusion 
 PRRs have been implicated in the pathophysiology of 
multiple immune disorders that affect the skin. Once 
evolved to protect us from pathogens, at which they are 
quite successful, they can become detrimental if signaling 
is excessive. Indications that PRRs are involved in the 
pathophysiology of multifactorial immune disorders are 
mainly based on genetic association studies and murine 
knockout models. Comprehensive endogenous expression 
analyses and functional studies are urgently needed to de-
termine their actual contribution to the pathophysiology. 
This will also lead to more targeted therapies, since immu-
nomodulation of PRRs seems a promising therapeutic ap-
proach to various immune disorders and malignancies.
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